research: future leptin blocker may treat triple negative breast cancer

Early studies by researchers at Temple University suggest that leptin levels may respond to a leptin blocker, a promising development for a new drug to add to the arsenal for treating triple-negative breast cancer. Leptin levels are elevated in 92 percent of cases of triple-negative breast cancer and help to fuel the growth of this aggressive type of breast cancer. It is a long way from studies of mice to approval for human subjects, but these early findings show that a leptin receptor blocker extended survival significantly with very few side effects.

Let’s keep an eye on this.

New peptide could be effective treatment for triple negative breast cancer. In, online publication 3-1-11

Laszlo Otvos Jr., Ilona Kovalszky, Mirko Riolfi, Rita Ferla, Julia Olah, Andras Sztodola, Kaushik Nama, Annamaria Molino, Quirino Piubello, John D. Wade, Eva Surmacz. Efficacy of a leptin receptor antagonist peptide in a mouse model of triple-negative breast cancer. In press, European Journal of Cancer 2-25-11

5 6 7 8
© 2004-2011 Donna Peach. All rights reserved.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s